Melittin Reprograms Tumor‐Associated Macrophages Through CD18 ‐Mediated Immunomodulation
Phytotherapy Research · 2026-11 · 40 (11) · 6201-6215
DOI: 10.1002/ptr.70431 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 20.08.2026. Verfasst von Ik-Hwan Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Melitten, Tumor-Associated Macrophages, Immunomodulation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, South Korea, Korea Institute for Advancement of Technology, Technology Commercialization Promotion Program.
Abstract (Originalsprache)
Tumor‐associated macrophages (TAMs), particularly the M2‐like subtype, contribute to an immunosuppressive tumor microenvironment and promote tumor progression. Melittin, a natural bioactive peptide derived from bee venom, has been reported to exert anticancer and immunomodulatory effects; however, the cellular targets and molecular mechanisms underlying its selective action on TAMs remain incompletely defined. This study aimed to investigate the immunomodulatory effects of melittin on TAM subsets and to identify the molecular determinant responsible for its selectivity toward M2‐like macrophages. Macrophage subsets were analyzed following melittin treatment using flow cytometry, gene expression analysis, and immunofluorescence. Binding interactions were assessed by biochemical and biophysical approaches. Tumor growth and immune cell composition were examined in wild‐type and CD18‐deficient mice. Melittin treatment selectively reduced M2‐like TAM populations while increasing infiltration of CD8 + cytotoxic T cells in tumor tissues. Mechanistic analyses revealed that melittin preferentially binds to the integrin subunit CD18 (ITGB2), which is enriched in M2‐polarized macrophages, leading to disruption of M2‐associated phenotypes in vitro. Notably, genetic deletion of CD18 abolished the M2‐suppressive and antitumor effects of melittin in vivo. These findings demonstrate that CD18 is functionally required for the immunomodulatory and antitumor activities of native full‐length melittin. This study provides mechanistic insight into the selective action of a natural bioactive peptide and supports its potential as a lead compound for natural product‐based immunomodulatory strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
- Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
- Twinpig Biolab Inc. R&D Center, Seoul, Republic of Korea.
ORCID-Profile: Ik-Hwan Han, Hyunju Lee, Eunbin Ko, Ilseob Choi, Soyoung Kim, Hyunsu Bae
Förderung
- Ministry of Science and ICT, South Korea
- Korea Institute for Advancement of Technology
- Technology Commercialization Promotion Program
Zitieren
APA
Han, I. H., Lee, H., Ko, E., Choi, I., Kim, S., Hwang, D. S., & Bae, H. (2026). Melittin Reprograms Tumor‐Associated Macrophages Through CD18 ‐Mediated Immunomodulation. Phytotherapy Research, 40(11), 6201-6215. https://doi.org/10.1002/ptr.70431
Vancouver
Han IH, Lee H, Ko E, Choi I, Kim S, Hwang DS, et al. Melittin Reprograms Tumor‐Associated Macrophages Through CD18 ‐Mediated Immunomodulation. Phytotherapy Research. 2026;40(11):6201-6215. doi:10.1002/ptr.70431
BibTeX
@article{Han2026,
author = {Han, Ik-Hwan and Lee, Hyunju and Ko, Eunbin and Choi, Ilseob and Kim, Soyoung and Hwang, Deok-Sang and Bae, Hyunsu},
title = {Melittin Reprograms Tumor‐Associated Macrophages Through CD18 ‐Mediated Immunomodulation},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {11},
pages = {6201--6215},
doi = {10.1002/ptr.70431}
}
EUVIMED